Literature DB >> 2824468

Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3.

M J Heeb1, F España, M Geiger, D Collen, D C Stump, J H Griffin.   

Abstract

Purified plasma and urinary protein C inhibitors (PCI) formed heparin-dependent complexes with activated protein C (APC) which were detected by immunoblotting after nondenaturing gel electrophoresis. Bands representing APC.PCI complexes were also seen on immunoblots after incubation of plasma with APC and heparin. The same immunoblot pattern of complexes was detected by three different methods: method A, monoclonal antibody to plasminogen activator inhibitor-3 (PAI-3, urinary urokinase inhibitor) + 125I-labeled anti-mouse IgG; method B, polyclonal antibodies to PCI + 125I-labeled purified plasma PCI; and method C, monoclonal antibody to protein C + 125I-protein C. Plasma depleted of PAI-3 by immunoadsorption with insolubilized monoclonal antibody to PAI-3 showed no detectable antigen or complexes with APC as visualized by methods A or B. This PAI-3-depleted plasma had less than 10% of the heparin-dependent inhibitory activity of normal plasma toward APC. Purified plasma PCI was fully reactive in an enzyme-linked immunoabsorbent assay for PAI-3, and plasma and urinary PCI inhibited urokinase activity in a heparin-dependent manner. These data indicate that heparin-dependent plasma and urinary PCI and PAI-3 are immunologically and functionally very similar if not identical. This observation identifies a new interrelation between the protein C anticoagulant and the fibrinolytic systems. In addition, plasma contains a heparin-independent inhibitor of APC which is not immunologically related to plasma PCI or to PAI-3.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824468

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

2.  Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein.

Authors:  L M Chen; L Chao; R K Mayfield; J Chao
Journal:  Biochem J       Date:  1990-04-01       Impact factor: 3.857

Review 3.  Modern treatment of pulmonary embolism.

Authors:  C M Kessler
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 4.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 5.  The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis.

Authors:  J Nip; P Brodt
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

Review 6.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

Review 7.  Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients.

Authors:  M T Nurmohamed; H R Büller; J W ten Cate
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 8.  Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors.

Authors:  R Khokha; D C Martin; J E Fata
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

9.  Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors.

Authors:  J S Rao; A Rayford; R A Morantz; B W Festoff; R Sawaya
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 10.  Thrombolytic therapy in the treatment of stroke.

Authors:  G J del Zoppo
Journal:  Drugs       Date:  1997       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.